Superworth

Rhythm Pharmaceuticals EPS RYTM

Diluted earnings per share by quarter and over the last twelve months, from 2016.

Last 12 months, to Jun 30, 2026
−$3.11
Latest quarter, Q2 FY26
−$0.73
Fiscal year 2025
−$3.11

Rhythm Pharmaceuticals' earnings per share was −$3.11 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.73.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$3.11n/a
FY2024−$4.35n/a
FY2023−$3.20n/a
FY2022−$3.48n/a
FY2021−$1.35n/a
FY2020−$3.05n/a
FY2019−$3.90n/a
FY2018−$2.38n/a
FY2017−$3.71n/a
FY2016−$2.86n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.73n/a−$3.11
Q1 FY26−$0.83n/a−$3.13
Q4 FY25−$0.73n/a−$3.11
Q3 FY25−$0.82n/a−$3.10
Q2 FY25−$0.75n/a−$3.01
Q1 FY25−$0.81n/a−$2.81
Q4 FY24−$0.72n/a−$4.35
Q3 FY24−$0.73n/a−$4.33
Q2 FY24−$0.55n/a−$4.36
Q1 FY24−$2.35n/a−$4.63
Q4 FY23−$0.70n/a−$3.20
Q3 FY23−$0.76n/a−$3.25

Against its peers

Companies in Drug Manufacturers - General nearest Rhythm Pharmaceuticals' size, closest first, today.

CompanyEPS, 12 monthsGrowth
RYTMRhythm Pharmaceuticals−$3.11
LGNDLigand Pharmaceuticals$9.40
KNSAKiniksa Pharmaceuticals International$0.97+2325% a year
AMRXAmneal Pharmaceuticals$0.49+4800% a year
ALKSAlkermes plc.$0.38−82% a year
TGTXTG Therapeutics$2.74+641% a year
PTGXProtagonist Therapeutics$1.03+47% a year
CORTCorcept Therapeutics$0.42−63% a year
INDVIndivior Pharmaceuticals$2.78+227% a year
ARQTArcutis Biotherapeutics$0.22
LQDALiquidia$1.39
Peer median$1.00

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Rhythm Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.